
CVRx (CVRX) Stock Forecast & Price Target
CVRx (CVRX) Analyst Ratings
Bulls say
CVRx is a commercial-stage medical device company with a proprietary platform technology, Barostim, designed to treat cardiovascular diseases by leveraging the power of the brain to address the imbalance of the Autonomic Nervous System. Despite a slight decrease in active accounts in Q4/26, the company expects to add approximately three territories per quarter and grow net accounts in the high single digits. Additionally, the recent implementation of Category I CPT codes should reduce reimbursement friction and improve commercial access, which could expand the total addressable market for Barostim. Overall, with strong financial results and market potential, we maintain a positive outlook on CVRx's stock.
Bears say
CVRx is seeing revenue growth and gross margin outperform their initial 2026 projections. However, the company's Q1 OpEx was higher than expected, and their number of active sites is slightly lower than anticipated. There is potential for future growth with the BENEFIT-HF trial, but current productivity levels and a decline in the company's comparative multiple lead to a lowered price target of $10.
This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.
CVRx (CVRX) Analyst Forecast & Price Prediction
Start investing in CVRx (CVRX)
Order type
Buy in
Order amount
Est. shares
0 shares